Drug Information

Drug General Information
Drug ID
D0T5PO
Former ID
DNC003593
Drug Name
ROLIPRAM
Drug Type
Small molecular drug
Indication Discovery agent Phase 2 [521483], [540724]
Structure
Download
2D MOL

3D MOL
Formula
C16H21NO3
InChI
InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
InChIKey
HJORMJIFDVBMOB-UHFFFAOYSA-N
CAS Number
CAS 61413-54-5
PubChem Compound ID
5092
PubChem Substance ID
611179, 841134, 855869, 3153149, 5146349, 7848845, 7980298, 8153132, 11121421, 11121901, 11362490, 11365052, 11367614, 11370251, 11370252, 11373215, 11375776, 11466952, 11468072, 11486743, 12013590, 15222043, 17405628, 22391521, 24278196, 26681488, 26719663, 26719664, 26752319, 26752320, 26752321, 26759453, 29224160, 46386779, 46386848, 46487946, 46514702, 47217030, 47365441, 47440514, 47811011, 48035380, 48185221, 48334758, 49635712, 49699213, 50039658, 50105263, 50105264, 50105265
Target and Pathway
Target(s) CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [534389]
Type IV phosphodiesterase Target Info Inhibitor [530753]
CGMP-specific 3',5'-cyclic phosphodiesterase Target Info Inhibitor [533856]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [551282]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
cGMP-PKG signaling pathwayhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling eventsR-HSA-418457:cGMP effectsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
References
Ref 521483ClinicalTrials.gov (NCT00011375) Rolipram to Treat Multiple Sclerosis. U.S. National Institutes of Health.
Ref 540724(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5260).
Ref 530753Bioorg Med Chem. 2010 Mar 15;18(6):2204-18. Epub 2010 Feb 8.In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
Ref 533856J Med Chem. 1994 Jun 24;37(13):2106-11.Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity.
Ref 534389J Med Chem. 1997 May 9;40(10):1417-21.Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
Ref 551282Discovery of micromolar PDE IV inhibitors that exhibit much reduced affinity for the [3H]rolipram binding site: 3-norbornyloxy-4-methoxyphenylmethylene oxindoles, Bioorg. Med. Chem. Lett. 5(17):1965-1968 (1995).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.